Dubai Holding and Palantir create joint venture Aither for AI transformation
ORLANDO - Nutriband Inc. (NASDAQ:NTRB), whose stock has surged over 58% year-to-date and currently trades at $7.15, announced Monday that company founder Gareth Sheridan has resumed his role as CEO, effective immediately. Sheridan returns to the position after a temporary leadership arrangement during which Co-Founder and Chairman Serguei Melnik served as CEO from August 10 to October 27, 2025.
According to the company’s press release, Sheridan will guide Nutriband through its 2025 framework toward the planned New Drug Application (NDA) filing in 2026 for AVERSA Fentanyl, an abuse-deterrent opioid patch. InvestingPro data shows the company maintains strong liquidity with a current ratio of 4.78 and holds more cash than debt on its balance sheet.
The AVERSA technology incorporates aversive agents into transdermal patches designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The company states the technology is protected by patents issued in 46 countries including the United States, Europe, Japan, and China.
Nutriband describes AVERSA Fentanyl as potentially becoming the first abuse-deterrent opioid patch of its kind. The company claims the product could reach peak annual U.S. sales of $80 million to $200 million, according to a market analysis report cited in the announcement.
The company indicated that while initially focusing on the U.S. market, it aims to eventually make the product available in major medical markets worldwide.
Nutriband Inc. primarily develops transdermal pharmaceutical products, with AVERSA Fentanyl serving as its lead product under development. With a market capitalization of $85.91 million and analysts setting a $15 price target, InvestingPro analysis suggests the stock may be undervalued. Subscribers can access 5 additional ProTips and comprehensive financial metrics to make informed investment decisions.
In other recent news, Nutriband Inc. reported a significant 50.87% year-over-year revenue increase for the first half of 2025, totaling $1,289,884. The company also disclosed that stock options and warrants exercised between February and July 2025 generated approximately $5.35 million in gross proceeds. Nutriband has initiated the commercial brand name development process for its abuse-deterrent fentanyl transdermal system, partnering with Brand Institute, a firm known for its pharmaceutical brand name expertise. Additionally, Nutriband has filed a provisional patent application to bolster intellectual property protection for its AVERSA™ abuse-deterrent transdermal technology. The application aims to enhance the deterrent properties of their opioid and stimulant patches. Furthermore, the U.S. Food and Drug Administration has granted a Type C Meeting for Nutriband’s AVERSA FENTANYL, scheduled for September 18, 2025, to discuss plans for the product’s approval and commercialization. These developments indicate Nutriband’s ongoing efforts to advance its product offerings and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.